Navigation Links
Advanced Life Sciences Receives Notice of Planned Cethromycin Review by FDA Advisory Committee

CHICAGO, Feb. 27 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), announced today that it has received notice from the U.S. Food and Drug Administration (FDA) that the agency's Anti-Infective Drugs Advisory Committee (AIDAC) is tentatively scheduled to meet on June 2, 2009, and will discuss the New Drug Application (NDA) for cethromycin, a new once-a-day oral antibiotic for the proposed indication of outpatient treatment of adults with mild-to-moderate community acquired pneumonia (CAP).


In November, 2008, the FDA filed the Company's NDA for cethromycin and established a target Prescription Drug User Fee Act (PDUFA) action date for the cethromycin NDA of July 31, 2009. Further details pertaining to the AIDAC meeting will be provided by Advanced Life Sciences upon receipt of additional information from FDA.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. For more information, please visit us on the web at

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health
2. Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results
3. Nasdaq Panel Grants Advanced Life Sciences Request for Continued Listing on Nasdaq Stock Market
4. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
5. Advanced Life Sciences to Present at the 11th Annual BIO CEO & Investor Conference
6. Queensland Facility for Advanced Bioinformatics (QFAB) Becomes a GeneGo Center of Excellence for the Asia Pacific Region
7. Advanced Instruments Makes Strategic Investment in Cantimer, Inc.
8. Pioneering Cancer Center Introduces Advanced Varian RapidArc(TM) Treatments for Cancer Patients in Central Germany
9. Jubilant Biosys Launches Legend NGSS(TM) Advanced Software Solution for High-Throughput Drug Molecule Screening
10. Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons
11. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... business and prospects remain fundamentally strong and highlights ... doxorubicin) recently received DSMB recommendation to continue the ... review of the final interim efficacy and safety ... Endpoint in men with heavily pretreated castration- and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
Breaking Biology Technology:
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
(Date:10/26/2015)... -- Delta ID Inc., a company focused on bringing secure ... announced its ActiveIRIS® technology powers the iris recognition feature ... NTT DOCOMO, INC in Japan . ... include iris recognition technology, after a very successful introduction ... 2015, world,s first smartphone to have this capability. ...
Breaking Biology News(10 mins):